厚生労働科学研究費補助金(がん対策推進総合研究事業(がん政策研究事業)) 分担研究報告書

医療情報収集・提供の仕組みの国際比較

研究分担者 永岩 麻衣子 サイニクス株式会社 ジェネラル・マネージャー 研究協力者 村松 綾子 サイニクス株式会社 チーフ・オペレーティング・オフィサー

研究要旨

がん登録等の推進に関する法律(がん登録推進法、平成25年法律第111号)に基づき集められた全国のがんの罹患の情報(全国がん登録情報)は、がんに係る調査研究やがん対策の企画立案又は実施のために利用できる。2019年から国立がん研究センターでは、「全国がん登録 情報提供の窓口」を開設し、全国がん登録情報の利用申請を受け付けていており、今後当該情報の利活用はさらに進むことが予想される。

そこで、本分担研究の目的は、任期となる三年間を通して、欧米におけるがん登録データを含む医療情報収集・提供・利用状況を調査し、調査結果を基に、我が国でのあり方を提言することである。

昨今の情報保護の厳格化を踏まえ、とりわけ欧州を中心に、がん登録情報を初めとする 医療情報の収集方法及び研究や行政利用での提供方法を調査した結果は、我が国のあり方 に参照できる。欧州で取り入れられているデータの提供方法、その安全性と簡便性、さら に利用方法や利用範囲について今後確認していきたい。

本年度は、調査票を作成した。調査票は、国際がん登録協議会(International Association of Cancer Registries)や欧州がん登録ネットワーク(European Network of Cancer Registries)のネットワークを介し、来年度より各国の統計担当者へ配布する。来年度の報告書では、調査結果を基に、諸外国における医療情報集・提供・利用状況についてまとめたい。本調査により、我が国の医療情報提供の仕組みを検討する上で、有益な基礎情報が収集できる。

A. 研究目的

がん登録等の推進に関する法律(がん登録推進法、平成25年法律第111号)に基づき集められた全国のがんの罹患の情報(全国がん登録情報)は、がんに係る調査研究やがん対策の企画立案又は実施のために利用できる。2019年から国立がん研究センターでは、「全国がん登録情報の代し、全国がん登録情報の利用申請を受け付けていており、今後当該情報の利活用はさらに進むことが予想される。

そこで、本分担研究の目的は、任期となる三年間を通して、欧米におけるがん登録データを含む医療情報収集・提供・利用状況を調査し、調査結果を基に、我が国でのあり方を提言することである。

B. 研究方法

本年度は、調査票を作成した(添付1)。 調査項目は10項目から成り、以下の通り である:

- ・ がん登録の仕組み(Cancer Registry Data)
- ・ がん検診制度(Cancer Screening)
- 死亡データ(Mortality Database)
- ・ 健康保険の請求データ(Health Insurance Claim Data)
- ・ バイオバンク(Biobank)
- · 人口動態調査(Census or other socio-demographic database)
- ・ その他の臨床系データについて (Other clinical database)
- ・ データリンケージについて(Data linkage)
- ・ データ利用に関して(Data usage)
- ・ 調査を実施する上での課題 (Barriers to conduct the research)

調査票は、国際がん登録協議会

(International Association of Cancer Registries) や欧州がん登録ネットワーク (European Network of Cancer Registries) のネットワークを介し、各国における統計担当者へ来年度より配布する。

C. 研究結果

昨今の情報保護の厳格化を踏まえ、とりわけ欧州を中心に、がん登録情報を初めとする医療情報の収集方法及び研究や行政利用での提供方法を調査した結果は、我が国のあり方に参照できる。次年度より実施する調査結果を基に、欧州で取り入れられているデータの提供方法、その安全性と簡便性、さらに利用方法や利用範囲について今後確認していきたい。

D. 考察

本調査票を基に、医療情報の収集や提供の仕組みについて国際比較を行うことが可能になるであろう。過去に、Siesling (2015)は、欧州におけるがん登録の仕組みの整理を行っている。本調査を実施することにより、より幅広い国々におけるがん登録ならびに医療情報の仕組み、その提供方法や利用状況を把握することが可能である。

我が国の医療情報提供の仕組みを検 討する上で、これらの情報は有益な基礎情 報となることが期待される。

E. 結論

本分担研究では、欧米におけるがん登録データを含む医療情報の収集・提供・利用状況を調査する。10項目から構成される調査票を、来年度より各国の統計担当者へ配布し、回答を収集する。調査結果は、来年度以降の報告書で纏める。本調査により、我が国の医療情報提供の仕組みを検討する上で、有益な基礎情報が収集できる。

F. 健康危険情報

なし

G. 研究発表

なし

H. 知的財産権の出願・登録情報

1. 特許取得

なし

2. 実用新案登録

なし

3. その他

なし

参考文献:

Siesling S. Louwman W.J. Kwast A et al. Use of cancer registries for public health and clinical research in Europe: Results of the European Network of Cancer Registries suevry among 161 population-based cancer registries during 2020-2012. Eur J Cancer. 2015 Jun;51(9):1039-49.

謝辞:

調査票の作成および分担研究の遂行に あたって終始指導いただきました国立が ん研究センター 松田智大先生に、深く感 謝の意を表します。

Overview of public use of cancer data Questionnaire

Contents

1.	Con	tact	4
	1.1.	Contact information	4
	1.2.	Sharing the answers	4
	1.3.	Do you have any comments to add before the submission of this questionnaire?	4
2.	Can	cer registry data	5
	2.1.	Data collection	5
	2.2.	Conditions of the data	5
	2.3.	Conditions of the data usage	6
3.	Can	cer screening	8
	3.1.	Data collection	8
	Please	indicate the modalities of screening programmes for any of the tumour types listed	
	below	, if carried out in your registration area:	8
	3.2.	Conditions of the data usage	9
4.	Moi	tality Database	11
	4.1.	Data collection	11
	4.2.	Conditions of the data usage	11
5.	Hea	lth Insurance Claim Database	13
	5.1.	Health insurance claim type	13
	5.2.	Conditions of the data	13
	5.3.	Conditions of the data usage	13
6.	Biok	pank	16
	6.1.	Biobank type	16
	6.2.	Conditions of the data	16
	6.3.	Conditions of the data usage	16
7.	Cen	sus or other socio-demographic database	19
	7.1.	Availability of data	19
	7.2.	Conditions of the data usage	19
8.	Oth	er clinical database	22
	8.1.	Type of data	22
9.	Data	a linkage	23
	9.1.	Linkable database	23
	9.2.	Linkage center	23
10). D	ata usage	24
	10.1.	Data usage in health policy	24

11.	Barriers to conduct a research	28
11.	.1. Privacy legislation	28
11.	.2. Technical issues	28
11	3 Technical issues	78

1. Contact						
1.1. Contact information						
1.1.1.Please enter your name						
1.1.2.Please enter your email address						
1.1.3.Name of the institute						
1.2. Sharing the answers						
Below, please select the level of sharing of identified answers to the other questions contained in this						
questionnaire.						
1.2.1.Other IACR members *						
□ Yes						
□ No						
1.2.2.Unrestricted public *						
□ Yes						
□ No						
1.3. Do you have any comments to add before the submission of this questionnaire?						

2.	Cancer	Cancer registry data					
2.1.	Data co	Data collection					
2.1.1	2.1.1.Registry type:						
	□ National						
		Regional					
		Hospital-based					
		No registry in the country					
		vered by PBCR					
	.Please i	ndicate the year that the registry activity started in the country					
		ndicate the current or most recent estimation of area covered by the registry (in km2):					
2.1.5	.Please (enter the current or most recent estimation of the size of the population covered by the					
	regis	try (in number of inhabitants)					
2.1.6		enter the year of reference for the number of inhabitants provided					
2.1.7		the data for the cancer registry retrieved or submitted:					
	Via t	ne treating doctors manually (physical notification form)?					
	By da	ata entry by designated professionals in the cancer registry?					
	Via a	utomatic submission from electronic health care records?					
	Via e	lectronic submission from (e.g.) pathology laboratories or hospital records systems?					
2.1.8	3.Please	describe how the follow-up items below are collected in your registry:					
	Vital	status					
	Date	of follow-up					
	Caus	e of death					
	Dista	nt metastasis					
	Recu	rrence					
	Trea	ment after the first course of treatment					
2.2.	Conditi	ons of the data					
2.2.1	2.2.1.To whom do the data belong?						
	Nati	onal/ Local Government					
	Rese	arch group/ Researcher					
	Univ	ersity, Hospital, etc.					

	l Medical organization						
	Private company						
	Others, please explain						
2.2.2.D	oes the law (or any subsidia	ry regulations) on priv	acy apply to the data	collection?			
	Yes						
	No						
2.2.3.U	nder this law (regulation), is	informed consent req	uired for a governme	nt, doctor, hospital or			
	researcher, to submit individual data to the database?						
	Yes						
	No						
2.2.4.If	informed consent is not req	uired for cancer regist	ration, what other da	ta privacy procedure			
	(if any) is being used (e.g. b	pecause the data are o	ollected anonymous)	?			
				····			
2.3. C	onditions of the data usage						
2.3.1.To	whom do the data belong?						
	National/ Local Governme	nt					
	Research group/ Research	er					
	University, Hospital, etc.						
	Medical organization						
	Private company						
	Others, please explain						
2.3.2.Is	a specific law regulating da	ta use in force?					
	Yes						
	No						
2.3.3.W	tho are authorized to use the	e individual data othe	r than published aggr	egated numbers?			
(1 Yes, :	2 No, 3 Other)						
		Non-anonymised	Anonymised individual	Aggregated data			
	individual data linkable data ²						
		to other data ¹					
National,	/ Local Government						
Research	n/ Education						
Private c	ompany						
Mass me	edia						

Others				
2.3.4.A	re foreigners allowed to use	the individual data ot	her than published a <u>c</u>	ggregated numbers?
	Yes			
	Yes, annnonymised data o	nly		
	Yes, under certain condition	ons		
	No			
2.3.5.A	re there any other condition	s for data usage (i.e. o	only for academic use,	have to be a
	member of a research team	estado entre destado do ser especia		
2.3.6.F	low long does it take to use t	he data generally fror		tion?
	Within a month			
	A couple of months			
	Longer than that			
2.3.7.F	lease describe the procedure	to have an access to	the data (i.e. online a	pplication)
2.3.8.1	s it free of charge to use the	data?		
	Yes			
	No			
2.3.9.1	s there any onsite center to u	se the data?		
	Yes			
	No			
2.3.10.	Are you allowed to share a	nd publish anonymise	d data on single indiv	iduals?
	Yes			
	Yes, under certain condition	ons		
	No			

3. Cancer screening

3.1. Data collection

Please indicate the modalities of screening programmes for any of the tumour types listed below, if carried out in your registration area:

			Is "method of detection in A		Any access to the screening database (directly or		
	Org	anisation	in your re	gistry? (1)	through reco	through record linkage)?	
	Invitations	Opportunistic	Yes	No	Yes	No	
Breast cancer							
Cervical cancer							
Ovary cancer							
Colorectal cancer							
Prostate cancer							
Malignant Melanoma							
Lung cancer							
Other cancer							

¹ According to the ENCR recommendations http://www.encr.com.fr/detection.pdf

3.1.1.A	re there screening programs for other cancer sites in your registration area?
3.1.2.D	o you routinely use the PBCR data for quality control of cancer screening?
	Yes
	No
3.1.3.Is	there an integrated database for cancer screenees?
	Yes
	No
3.1.4.Ta	o whom do the data belong?
	National/ Local Government
	Research group/ Researcher
	University, Hospital, etc.
	Medical organization
	Private company
	Others, please explain

	No			
3.1.6.0		n), is informed consent red		it, doctor, ho
-		ndividual data to the data	ibase?	
	Yes			
10	No	t required for cancer regist	tration what other dat	a neivaav ne
3.1.7.1	2 3	e.g. because the data are o		8 86
	(i) dily) is being used (e			
3.2. (Conditions of the data us	sage		
	To whom do the data bel			
	National/ Local Gover			
	Research group/ Rese			
	University, Hospital, e			
	Medical organization			
	Private company			
	Others, please explain			
3.2.2.1	s a specific law regulatin	g data use in force?		
	Yes			
	No			
<i>3.2.3</i> .1	Who are authorized to us	se the individual data othe	r than published aggre	gated numb
(1 Yes,	, 2 No, 3 Other)			
		Non-anonymised	Anonymised individual	Aggregated
		individual data linkable	data ²	
		to other data ¹		
Nationa	al/ Local Government			
Researc	ch/ Education			
Private	company			
Mass m	nedia			
Others				

	Yes, under certain conditions			
	No			
3.2.5.A	re there any other conditions for data usage (i.e. only for academic use, have to be a			
	member of a research team, etc.)?			
3.2.6.H	low long does it take to use the data generally from the date of application?			
	Within a month			
	A couple of months			
	Longer than that			
3.2.7.P	lease describe the procedure to have an access to the data (i.e. online application)			
3.2.8.Is	it free of charge to use the data?			
	Yes			
	No			
3.2.9.Is	there any onsite center to use the data?			
	Yes			
	No			
3.2.10.	Are you allowed to share and publish anonymised data on single individuals?			
	Yes			
	Yes, under certain conditions			

4.	4. Mortality Database							
4.1.	4.1. Data collection							
4.1.1	4.1.1.Mortality data coverage:							
		National						
		Regional						
		Hospital-based						
		No mortality data in the country						
4.1.2	?.Area cov	vered by the mortality database						
4.1.3	3.Please ir	ndicate the year that the mortality data activity started in the country						
4.1.4	I.Please d	escribe the procedure to collect death certificates to make up the database						
		law (or any subsidiary regulations) on privacy apply to the data collection?						
	Yes							
	No							
4.1.6	5.Under th	is law (regulation), is informed consent required for a government, doctor, hospital or						
	resea	rcher, to submit individual data to the database?						
	Yes							
	No							
4.1.7	7.If inform	ed consent is not required for data collection, what other data privacy procedure (if						
	any) i	s being used (e.g. because the data are collected anonymous)?						
4.2.	Conditio	ons of the data usage						
4.2.1	.To whor	n do the data belong?						
	Natio	nal/ Local Government						
	Resea	arch group/ Researcher						
	Unive	ersity, Hospital, etc.						
	Medi	cal organization						
	Priva	te company						

.....

□ Yes

No

☐ Others, please explain

4.2.2.Is a specific law regulating data use in force?

4.2.3. Who are authorized to use the individual data other than published aggregated numbers? (1 Yes, 2 No, 3 Other)

		Non-anonymised	Anonymised individual	Aggregated data
		individual data linkable	data ²	
		to other data ¹		
National,	/ Local Government			
Research	/ Education			
Private c	ompany			
Mass me	edia			
Others				
4.2.4.A	re foreigners allowed to use	the individual data ot	her than published ag	gregated numbers?
	Yes			
	Yes, annnonymised data or	nly		
	Yes, under certain condition	ons		
	No			
4.2.5.A	re there any other condition:	s for data usage (i.e. c	only for academic use,	have to be a
	member of a research tean	n, etc.)?		
4.2.6.H	ow long does it take to use t	he data generally fror	m the date of applicat	ion?
	Within a month			
	A couple of months			
	Longer than that			
4.2.7.Pl	ease describe the procedure	to have an access to	the data (i.e. online a	pplication)
4.2.8.Is	it free of charge to use the o	data?		
	Yes			
	No			
4.2.9.Is	there any onsite center to u	se the data?		
	Yes			
	No			
4.2.10.	Are you allowed to share a	nd publish anonymise	d data on single indivi	duals?
	Yes			
	Yes, under certain condition	ons		

	No			

5. H	ealth Insurance Claim Database
5.1. H	lealth insurance claim type
5.1.1.H	lealth insuran type:
	□ National
	□ Regional
	□ Private
	☐ No health insurance database in the country
5.1.2.P	lease describe the procedure to collect health insurance claim to make up the database
5.2. C	conditions of the data
5.2.1.T	o whom do the data belong?
	National/ Local Government
	Research group/ Researcher
	University, Hospital, etc.
	Medical organization
	Private company
	Others, please explain
5.2.2.0	oes the law (or any subsidiary regulations) on privacy apply to the data collection?
	Yes
	No
5.2.3.U	Inder this law (regulation), is informed consent required for a government, doctor, hospital or
	researcher, to submit individual data to the database?
	Yes
	No
5.2.4.1	finformed consent is not required for cancer registration, what other data privacy procedure
	(if any) is being used (e.g. because the data are collected anonymous)?
5.3. C	onditions of the data usage
5.3.1.T	o whom do the data belong?
	National/ Local Government
	Research group/ Researcher
	University, Hospital, etc.

	Medical organization				
	Private company				
	Others, please explain				
5.3.2.Is	a specific law regulating da	ta use in force?			
	Yes				
	No				
5.3.3.W	tho are authorized to use the	e individual data othe	r than published aggr	egated numbers?	
(1 Yes, :	2 No, 3 Other)				
		Non-anonymised	Anonymised individual	Aggregated data	
		individual data linkable	data ²		
		to other data ¹			
National,	/ Local Government				
Research	/ Education				
Private c	ompany				
Mass me	edia				
Others					
5.3.4.Aı	re foreigners allowed to use	the individual data ot	her than published ag	gregated numbers?	
	Yes				
	- 1.5) and conditions				
	No				
5.3.5.Are there any other conditions for data usage (i.e. only for academic use, have to be a					
	member of a research tean	n, etc.)?			
5.3.6.How long does it take to use the data generally from the date of application?					
	Within a month				
	A couple of months				
	Longer than that				
5.3.7.Please describe the procedure to have an access to the data (i.e. online application)					
5 2 0 1	it free of charge to use the o	data2			
5.5.6.IS	Yes	autu:			
	No				
	there any onsite center to u	se the data?			
J. J. J. 13	CHECK GHIV CHANGE CENTER TO U	JE LIZE WULU;			

	Yes
	No
5.3.10.	Are you allowed to share and publish anonymised data on single individuals?
	Yes
	Yes, under certain conditions
	No

6.	Biob	ank	
6.1.	Biob	ank	type
6.1.	1.Biob	ank	type:
			National
			Regional
			Hospital-based
			Academic
			No biobank in the country
6.1.2	2.Plea	se in	dicate the year that collection of samples in the biobank started in the country
6 2	Con	ditio	ns of the data
			do the data belong?
U.Z			nal/ Local Government
E			rch group/ Researcher
			rsity, Hospital, etc.
_			ral organization
			e company
			s, please explain
			s, piedse expiain
6.2.2	 2.Doe		law (or any subsidiary regulations) on privacy apply to the data collection?
] Y	es	
	1 N	lo	
6.2.3	3.Und	er th	is law (regulation), is informed consent required for a government, doctor, hospital or
	re	esear	cher, to submit individual data to the database?
] Y	es	
] N	lo	
6.2.4	4.If in	forme	ed consent is not required for cancer registration, what other data privacy procedure
	(i	f any) is being used (e.g. because the data are collected anonymous)?
6.3.	Con	ditio	ns of the data usage
			do the data belong?
			nal/ Local Government
			rch group/ Researcher
			rsity, Hospital, etc.

	Medical organization					
	Private company					
	Others, please explain					
6.3.2.Is	a specific law regulating da	ta use in force?				
	Yes					
	No					
6.3.3.W	ho are authorized to use the	e individual data othe	r than published aggr	egated numbers?		
	2 No, 3 Other)					
		Non-anonymised	Anonymised individual	Aggregated data		
		individual data linkable	data ²			
		to other data ¹				
National,	/ Local Government					
Research	n/ Education					
Private c	ompany					
Mass me	edia					
Others						
6.3.4.AI	re foreigners allowed to use	the individual data ot	her than published ag	ı garegated numbers?		
	Yes			ON STORY STORY OF STORY STORY OF STORY		
	Yes, annnonymised data or	nly				
	Yes, under certain condition					
	No					
6.3.5.Are there any other conditions for data usage (i.e. only for academic use, have to be a						
	member of a research team, etc.)?					
6.3.6.How long does it take to use the data generally from the date of application?						
	Within a month	_				
	A couple of months					
	Longer than that					
6.3.7.Please describe the procedure to have an access to the data (i.e. online application)						
6.3.8.Is	it free of charge to use the o	data?				
	Yes					
	No					
6.3.9.Is	there any onsite center to u	se the data?				

	Yes
	No
6.3.10.	Are you allowed to share and publish anonymised data on single individuals?
	Yes
	Yes, under certain conditions
	No

7. Census or other socio-demographic database

7.1. Availability of data

7121 711 anabinty of water			
	Non-anonymised	Anonymised individual	Aggregated data
	individual data linkable	data2	
	to other data1	0	
Eating habit			
Smoking habit			
Alcohol intake			
Household income			
Education			
Profession			

¹Individual data in which the full identity of the patient has at least a key ID even the original identifiable variables are remove, e.g. the name and address, date of birth, etc., and it remains possible to link the record to the other database individually

²Individual data in which the identity of the person has been disguised by removal of a part or all identification, e.g. the name and address, date of birth, etc., and impossible to link the record to the other database individually. However, the data have geographical information to realize ecological studies.

7.1.1.Populatio	on data type:
	Census
	Civil registration
	Other estimation
7.1.2.Please de	escribe kind of the database

7.2. Conditions of the data usage

	12-AV
.2.1.Tc	whom do the data belong?
	National/ Local Government
	Research group/ Researcher
	University, Hospital, etc.
	Medical organization
	Private company

	Others, please explain			
7221	s a specific law regulating da	ita use in force?		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Yes	ta use myoree.		
_	No			
_	Who are authorized to use th	e individual data othe	r than published agan	egated numbers?
	2 No, 3 Other)	e marriadar adia otne	. trian pabrished aggre	igatea nambers.
(= :==/		Non-anonymised	Anonymised individual	Aggregated data
		individual data linkable	data ²	
		to other data ¹		
Nationa	ıl/ Local Government			
Researc	:h/ Education			
Private	company			
Mass m	edia			
Others				
7.2.4.	Are foreigners allowed to use	the individual data ot	her than published ag	gregated numbers?
	Yes			
	Yes, annnonymised data o	nly		
	Yes, under certain condition	ons		
	No			
7.2.5.A	Are there any other condition	s for data usage (i.e. c	only for academic use,	have to be a
	member of a research tear	m, etc.)?		
7.2.6.H	low long does it take to use	the data generally from	m the date of applicat	ion?
	Within a month			
	A couple of months			
	Longer than that			
7.2.7.F	Please describe the procedure	e to have an access to	the data (i.e. online a	oplication)
7.2.8.1	s it free of charge to use the	data?		
	Yes			
	No			
7.2.9.1	s there any onsite center to ເ	ise the data?		
	Yes			
П	No			

7.2.10.	Are you allowed to share and publish anonymised data on single individuals?
	Yes
	Yes, under certain conditions
	No

8. Other clinical database

8.1. Type of data

8.1.1. What kind of other clinical databases are available in the country?

	Non-anonymised individual data linkable to other data 1	Anonymised individual data ²	Aggregated data
Genetic information of cancer patients			
Academic association based clinical			
database			

8.1.2.Please indicate the year that collection of samples in the biobank started in the country	

9. Data linkage

9.1. Linkable database

9.1.1. Which of the listed data are individually linked to each other in your country? For each of the used data sources please indicate the type of inquiry best describing the current practice.

						10 .2	6	
	Cancer registry data	Cancer screening data	Mortality data	Health insurance claim	Biobanks	Census	rocorde	Pathology or other laboratories
Cancer								J.
registry								
data								-
Cancer								
screening								
data								
Mortality								i.
data								
Health								
insurance								
claim								
Biobanks								
Census		3						
Hospital								
records								
Pathology		7						
or other								
laboratories	5							
Pharmacist:	5							
Research								
studies								
<u>.</u>								0
	L.	1			1			

¹⁼Nationally, 2=Regionally, 3=Project-based

9.2.	Linkage center
------	----------------

9.2.1.A	re there organizations specialized in linkage of several individual database?
	Yes
	No

10. Data usage

10.1. Data usage in health policy

10.1.1. Please describe the contribution of your registry to the description of cancer burden or evaluation of cancer control by selecting the applicable answer below:

	Routine, regular,	Occasional, ad- hoc	Never
	frequent		
Cancer control in general			
Cancer incidence rates			
Cancer survival			
Cancer mortality rates			
Development of national cancer control strategies			
Evaluation of national cancer control strategies			
Clinical audits on diagnosis/staging			
Clinical audits on treatment			
Clinical audits on waiting times			
Clinical audits on multidisciplinary care			
Evaluation of adherence to clinical guidelines for diagnosis			
Evaluation of impact of clinical guidelines for diagnosis			
Evaluation of adherence to clinical guidelines for			
treatment			
Evaluation of impact of clinical guidelines for treatment			
Improvement of cancer care projects			
Cancer screening evaluation			
Evaluation of radiation systems use			
Evaluation of usage of Computed Axial Tomography (CT)			
Evaluation of usage of Positron Emission Tomography			
(PET)			500
Evaluation of usage of magnetic resonance technique			

¹⁼Nationally, 2=Regionally, 3=Project-based

10.1.2. Please select the status of the private sector's use of each data item in the following list (Some of the questions are duplicated from the previous sections, but please kindly answer them again):

	Α.	Private	В.	Private	(if the answer is	No, private
		sector can		sector can	A or B) Can	sector cannot
		use		use with	private sector	use.
		without		application	can use non-	
		application			anonymous	
					data?	
Cancer incidence rates						
Cancer survival						
Cancer mortality rates						
Staging at diagnosis						
Initial treatment data						
Subsequent treatment data						
Recurrence / progression rates						
Biomarker testing rates						
Biomarkers						
Census or other socio-demographic database						

10.1.3. (showing the data for those its answer for 10.1.2. is A or B above) Does the private sector need to pay for using the data?

	Yes	No	
Cancer incidence rates			
Cancer survival			
Cancer mortality rates			
Staging at diagnosis			
Initial treatment data			
Subsequent treatment data			
Recurrence / progression rates			
Biomarker testing rates			
Biomarkers			

Census or other socio-demographic database	
--	--

10.1.4. (showing the data for those its answer for 10.1.2. is A or B above) Can private sector use the data for themselves (e.g. to make business decisions) or do they need to make the data public and give it back to society at large?

	Private sector	Private sector
	can use for	should publish
	their own	the data
	usage	
Cancer incidence rates		
Cancer survival		
Cancer mortality rates		
Staging at diagnosis		
Initial treatment data		
Subsequent treatment data		
Recurrence / progression rates		
Biomarker testing rates		
Biomarkers		
Census or other socio-demographic database		

10.1.5. (showing the data for those its answer for 10.1.2. is A or B above) Can the private sector use the data to apply for approval of a drug or medical device?

	Yes, private	No, private
	sector can use	sector cannot
	the data for	use the data for
	apply approval	apply approval
Cancer incidence rates		
Cancer survival		
Cancer mortality rates		
Staging at diagnosis		
Initial treatment data		
Subsequent treatment data		
Recurrence / progression rates		
Biomarker testing rates		

Biomarkers	
Census or other socio-demographic database	-

11. Barriers to conduct a research

11.1. Pr	ivacy legislation
11.1.1.	Have you experienced barriers to use the cancer data due to privacy legislation (e.g. PIN is
	not allowed to be used in medical research)?
	Yes, please explain
	No
11.2. Te	echnical issues
11.2.1.	Have you experienced barriers to use the cancer data due to technical issues (e.g. only
	initial of the names recorded in XX database)?
	Yes, please explain
	No
11.3. Te	echnical issues
11.3.1.	Please provide a short description (with examples) of any legal or ethical problems in public
	usage of cancer data, in cancer control planning/evaluation, quality control of medical acts
	and research?